Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.


MCWF (Amplimune) Shows Potential as a Preventative Treatment to Reduce Metritis Incidence in Dairy Cows

An abstract presented at the 2024 International Embryo Technology Society meeting summarizes a research study showing that a single treatment of Amplimune 7 days after parturition may help prevent metritis in dairy cows.

mare and foal in a field

Settle® Now Available in Canada

Settle® immunotherapy for equine endometritis is now available in Canada. It's also sold in the USA, Australia, New Zealand and UAE. Settle is compatible with conventional treatments and is safe with natural breeding or AI.

close up of a mare and foal

Settle® Approved for Canadian Market

NovaVive's immunotherapy for equine endometritis, Settle®, has received approval for sale in Canada from the Canadian Food Inspection Agency (CFIA). The product is expected to launch in the first quarter of this year.

MCWF Helps Improve Pregnancy per Embryo Transfer in Dairy Recipients with One Lactation

An abstract has been presented at the 2023 AETA & CETA/ACTE Joint Convention in Orlando, FL summarizing a study showing a positive effect of MCWF (Amplimune) on pregnancy per embryo transfer for dairy cows with one lactation.

foal with mare in field

Positive Data from Endometrial Cups Study with Settle® Presented at International Symposium

Data from a U.S. study using NovaVive's immunotherapy for equine endometritis, Settle®, to treat endometrial cups was presented today at the International Symposium on Equine Reproduction (ISER) in Foz do Iguaçu, Brazil.

beef calf with cow in a field

MCWF (Amplimune) Offers an Alternative for Herd Health as FDA Further Restricts Antibiotics

Effective in June, 2023, all over-the-counter bovine antibiotics in the U.S. will be switched to prescription-only status. Amplimune immunotherapy offers an alternative to antibiotics that does not require a prescription.

Sign up to stay up-to-date with NovaVive news.